Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12463989 | 0.92 | KIF11 (0.73) | KIF11 | |
| SCHEMBL12393605 | 0.91 | KIF11 (0.77) | KIF11 | |
| SCHEMBL12536915 | 0.89 | KIF11 (0.65) | KIF11 | |
| SCHEMBL12393574 | 0.85 | KIF11 (0.57) | KIF11 | |
| SCHEMBL14264763 | 0.85 | KIF11 (0.63) | KIF11 | |
| SCHEMBL14154542 | 0.83 | KIF11 (0.91) | KIF11 | |
| SCHEMBL14264765 | 0.81 | KIF11 (0.56) | KIF11 | |
| SCHEMBL6515608 | 0.81 | KIF11 (0.71) | KIF11 | |
| SCHEMBL5107138 | 0.81 | KIF11 (0.79) | KIF11 | |
| SCHEMBL5113848 | 0.81 | KIF11 (0.71) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763628-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7671200-B2 | Quinazolinone KSP inhibitors | CYTOKINETICS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7589098-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080182864-A1 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. | 2008-07-31 | — | — | US | disclosed |
| US-7294634-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070254902-A1 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. | 2007-11-01 | — | — | US | disclosed |
| US-7230000-B1 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INCORPORATED (US) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254902-A1 | Methods and compositions utilizing quinazolinones | KIF5B, KIF5C, KIF2C | KIF11 22/4885 |
| US-20080182864-A1 | Methods and compositions utilizing quinazolinones | KIF5B, KIF5C, KIF2C | KIF11 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.